

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION OF POWER OF ATTORNEY, NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


INTERMUNE INC., the owner of the entire right, title and interest in the attached listing of U.S. patent applications (Schedule A), hereby revokes all Powers of Attorney previously given in such patent applications. INTERMUNE INC. is the Assignee of the entire right and interest in each of these U.S. patent applications, as evidenced by the documentary evidence of the chain of title from the original owner to the Assignee, recorded in the Assignment records of the office at the reel/frame numbers indicated on Schedule A.

INTERMUNE INC. hereby appoints the attorneys and/or agents associated with customer number 89229 to prosecute these patent applications and transact all business in the U.S. Patent and Trademark Office.

Please recognize and change the correspondence address for the patent applications listed in Schedule A to the address associated with customer number 89229:

MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300

INTERMUNE INC.



Name: John Bendrick  
Title: Vice President, Intellectual Property, InterMune, Inc.  
Date: March 2, 2010

Schedule A

US Patent Applications					
MGB Reference	Application Number	Filing or 371 (c) Date	Title	Ref/Frame	
30481/30042	60/327,743	10/5/2001	Methods of treating liver fibrosis and hepatitis C virus infection	013214/0400	
30481/30044	60/340,194	7/4/2003	Compositions and methods for treating viral infections	014749/0016	
30481/30038	60/3471,404	5/16/2003	Hybrid chemo-kine receptor ligands and methods of use thereof	014480/0790	
30481/30046	60/3471,841	5/16/2003	Combination ILN therapy	015175/0822	
30481/30046A	60/345,474	7/8/2003	Combination ILN therapy for proliferative disorders	015175/0822	
30481/3004613	60/351,415	10/14/2003	Interferon-gamma and TNF-alpha antagonist combination therapy for the treatment of fibrotic diseases	015451/0312	
30481/30046C	60/351,280	10/14/2003	Combination therapy for the treatment of fibrotic diseases	014488/0659	
30481/3004612	60/351,259	10/14/2003	Combination therapy for the treatment of fibrotic diseases	014488/0659	
30481/3004615	60/3514,173	10/24/2003	Combination therapy for treating proliferative disorders	015531/0013	
30481/30047	60/3511,169	10/14/2003	Combination therapy for the treatment of viral diseases	014295/0659	
30481/300461F	60/3561,940	4/13/2004	Combination therapy for the treatment of fibrotic diseases	014282/0107	
30481/30048	60/3579,625	6/14/2004	Interferon compositions and methods of use thereof	014986/0522	
30481/30042A	10/490,457	8/16/2004	Methods of treating liver fibrosis and hepatitis C virus infection	015241/0447	
30481/30040	60/460,074	3/8/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections	015818/0726	
30481/30050	60/468,631	4/5/2005	Method of treating alphavirus infection	016089/0180	
30481/30039	60/482,544	5/18/2005	Non-natural chemokine receptor ligands and methods of use thereof	017138/0709	
30481/30048A	11/153,864	6/14/2005	Interferon compositions and methods of use thereof	018174/0953	
30481/30040P	60/707,891	8/12/2005	Use of alpha-glucosidase inhibitors to treat alphavirus infections	016804/0339	
30481/30043B	10/254,631	8/12/2005	Interferon drug therapy for the treatment of viral diseases and liver fibrosis	017593/0867	
30481/30044A	10/552,020	10/3/2005	Compositions and methods for treating viral infections	016799/0876	
30481/30046G	10/555,390	11/2/2005	Combination therapy for proliferative disorders	014986/0522	
30481/30049A	11/256,634	2/17/2006	Biomarkers for predicting liver fibrosis treatment efficacy	017645/0626	

US Patent Applications			
MGB Reference	Application Number	Filing or 371 (c) Date	Title
30481/3403N/A	10/555,735	1/1/30/2006	Synthetic chemokine receptor ligands and methods of use thereof
30481/30041	60/983,854	1/0/30/2007	HCV Genotyping and phenotyping assays
30481/30041P	61/043,020	4/7/2008	HCV Genotyping and phenotyping
30481/30039A	11/091,3768	5/23/2008	Non-natural chemokine receptor ligands and methods of use thereof
30481/30041A	12/262,111	1/0/30/2008	HCV Genotyping and phenotyping
30481/300403	12/617,676	1/1/12/2009	Use of alpha-glucosidase inhibitors to treat alphavirus infections
			(023698/0792)

US Patents			
MGB Reference	Application Number	Filing or 371(c) Date	Title
30481/30040A	11/370,335	3/7/2006	7,638,488 Use of alpha-glucosidase inhibitors to treat alphavirus infections
			(017758/0555)